Dr. Bryan P. Schneider, MD

Dr. Schneider practices at IU Health Methodist Hospital in Indianapolis, Indiana, part of Indiana University Health.

Dr. Schneider's NPI, 1811953433, was assigned on April 22, 2006. Dr. Schneider graduated from Indiana University School Of Medicine in 1999. Dr. Schneider's Indiana license number on file is 01053603.

Dr. Schneider's primary practice is IU Health Methodist Hospital, at 1701 N Senate Blvd, Indianapolis, IN 46202 in Marion County. The practice phone is (317) 962-2000.

Dr. Schneider's primary practice is IU Health Methodist Hospital in Indianapolis, Indiana, part of Indiana University Health. Dr. Schneider is also affiliated with IU Health Bloomington Hospital. The medical group on file is IU Health Medical Group. Dmand AI also links Dr. Schneider to 3 more hospitals, 2 group practices and clinics, 1 behavioral health center and 1 medical group, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Schneider practices, 8 sites in all. Vendor and product names are available with a free account.

Hematology and oncology is Dr. Schneider's primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Dr. Schneider is board certified in medical oncology by the American Board of Internal Medicine. Dr. Schneider has a license on file in Indiana.

Dmand AI lists breast cancer, lung cancer and prostate cancer among the conditions Dr. Schneider treats.

CMS data shows 307 Medicare services from Dr. Schneider across 5 procedure codes in 2024, for 186 Medicare patients. Medicare paid $22,876 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 186 Medicare patients who saw Dr. Schneider in 2024. The largest group is 65 to 74, with 104 patients. 75% of them have cancer, and 68% have high blood pressure. 9% are also on Medicaid. Their average risk score is 1.48, where 1.00 is the Medicare average.

Across all payers, Dmand AI patient panel data puts Dr. Schneider's median patient age at 63, with 80% women.

In 2024, Dr. Schneider wrote 635 Medicare Part D claims for 115 patients. 88% of them were for generic drugs. CMS names the drug for 543 of them, across 17 drugs with 11 or more claims each, at $524,118 in total drug cost. In 2023, CMS named 390 claims across 9 drugs.

Dr. Schneider accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Schneider as offering telehealth.

Dmand AI links 192 papers to Dr. Schneider, published from 2006 to 2025. 2022 was the busiest year, with 13. The most frequent topics are Breast Neoplasms, Antineoplastic Combined Chemotherapy Protocols and Paclitaxel. Dr. Schneider has published most often in J Clin Oncol. Dr. Schneider's most frequent co-authors are George Willard Sledge, MD, Tarah Jean Ballinger, MD and Nawal M. Kassem, MD.

Dmand AI links Dr. Schneider to 10 clinical trials, 3 of them phase 2 studies. 5 are still active or recruiting. Conditions studied include Breast Neoplasms, Breast Diseases and Breast Neoplasms, Male. National Cancer Institute (NCI) sponsors the most, 3. Open Payments lists research payments to Dr. Schneider that name 1 trial.

CMS Open Payments shows 15 general payments to Dr. Schneider from 7 drug and device companies from 2016 to 2025. Speaker and faculty fees make up the largest share, 50% of the total. Eli Lilly and Company paid the most, $7,921. It also lists 1 research payment totaling $95 in 2018, naming 1 clinical trial.

Dmand AI lists 8 awards for Dr. Schneider, most recently “Forty under 40” in 2012.

Dr. Schneider graduated from Indiana University School Of Medicine in 1999. Dr. Schneider is a member of ASCO.

Dr. Schneider is in network with 17 carriers, including Aetna, Elevance and Blue Cross Blue Shield of Michigan. PPO plans come from the most carriers, 11. Check the plan with the practice before a visit.